Methotrexate in the treatment of penile carcinoma

Abstract
Eight patients with epidermoid carcinoma of the penis received methotrexate, five with high-dose methotrexate, 250–1500 mg/m2 with citrovorum rescue Q 2–4 weeks, and three with low-dose methotrexate, 0.5–3.0 mg/kg weekly. Three (38%) patients achieved a complete or partial remission which persisted for 11, 3 and 2 months, respectively. Methotrexate appears to be an active agent in the treatment of advanced penile cancer.